Divi's Laboratories revenue and financials
₹9,412.00Change from previous close: +2.35%Absolute change: +₹216.00
In the fiscal year ended March 2026, Divi's Laboratories reported revenue of ₹104.76B (+12.34% year over year). Net income was ₹25.68B, a net margin of 24.5%.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +12.34%
- FY to Mar 2026 vs FY to Mar 2025
- Net income growth
- +17.21%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- 24.5%
- FY to Mar 2025: 23.5%
Financial data
Amounts in millions of INR; per-share values in INR; shares in millions.
| Item | FY to Mar 2026 | FY to Mar 2025 | FY to Mar 2024 | FY to Mar 2023 |
|---|---|---|---|---|
| Total revenue | 104,760 | 93,250 | 77,960 | 76,650 |
| Cost of revenue | 42,810 | 38,700 | 32,690 | 31,780 |
| Gross profit | 61,950 | 54,550 | 45,270 | 44,870 |
| Selling, general and administrative | 3,160 | 2,790 | 2,150 | 2,400 |
| Research and development | 400 | 270 | 350 | 300 |
| Operating income | 29,790 | 25,710 | 18,320 | 20,270 |
| EBIT | 34,110 | 29,180 | 21,660 | 23,690 |
| EBITDA | 38,740 | 33,200 | 25,440 | 27,120 |
| Interest expense | 230 | 20.0 | 30.0 | 0.0 |
| Pre-tax income | 33,880 | 29,160 | 21,630 | 23,690 |
| Income tax | 8,200 | 7,250 | 5,630 | 5,450 |
| Net income | 25,680 | 21,910 | 16,000 | 18,240 |
| Net income to common shareholders | 25,680 | 21,910 | 16,000 | 18,240 |
| Basic EPS | 96.75 | 82.53 | 60.27 | 68.69 |
| Diluted EPS | 96.75 | 82.53 | 60.27 | 68.69 |
| Average shares (basic) | 265 | 265 | 265 | 265 |
| Average shares (diluted) | 265 | 265 | 265 | 265 |